Johnson & Johnson Earnings Top; Dow Giant Falls Amid Lowered OutlookInvestors Business Daily • 10/15/24
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 studyPRNewsWire • 10/15/24
Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed SignalsBenzinga • 10/14/24
Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady GrowthSeeking Alpha • 10/11/24
TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitisPRNewsWire • 10/10/24
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patientsGlobeNewsWire • 10/10/24
Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/08/24
Johnson & Johnson (JNJ) Halts TAR-200 Bladder Cancer Trial, Future FDA Plans RemainGuruFocus • 10/08/24